Trial Profile
A Phase 2B, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study to Investigate the Efficacy, Mechanism of Action, Pharmacokinetics, Safety and Tolerability of the mGluR5 Negative Allosteric Modulator ADX10059 as Monotherapy in Patients With Gastroesophageal Reflux Disease (GERD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Raseglurant (Primary)
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- Sponsors Addex Therapeutics
- 23 Oct 2010 Results presented at the 18th United European Gastroenterology Week.
- 06 May 2010 Results of the patients evaluated mechanisitically were presented at Digestive Disease Week 2010.
- 05 May 2010 Results were presented at Digestive Disease Week 2010